ClinicalTrials.gg
RecruitingNCT06636435Updated Jun 17, 2026

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer

A Phase 1 interventional study of CBA-1205 Part 1 and CBA-1205 Part 2 in Solid Tumors, Hepatocellular Carcinoma (HCC) and Malignant Melanoma, sponsored by Chiome Bioscience Inc.. Recruiting at 5 sites in Japan. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Chiome Bioscience Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 3 months after the study started (first participant enrolled Jun 2020, registered Sep 2024).
  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in Carcinoma, Hepatocellular with a site in Japan — 17 open to participants now, 32 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Japan.

Planned enrollment
73rd of 103
66 · median 182
Started
2020
with 3 others
Phase 1
29 of 115
5 open now
Primary completion
2027-06
later than 14 of 31 live
Registered
107th of 115
by date

Among the 115 studies in Carcinoma, Hepatocellular with a site in Japan, this one is the 73rd largest by planned enrollment of the 103 interventional ones that give a count, is one of 4 that started in 2020, is one of 29 in phase 1, reaches primary completion later than 14 of the 31 other live ones, and was the 107th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 115 studies in Carcinoma, Hepatocellular with a site in Japan are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Carcinoma, Hepatocellular with a site in Japan, or all of them as a file.
02

Study summary

In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5). The purpose of this FIH study is to evaluate the safety and tolerability profile of CBA-1205.

Read the detailed description

To evaluate safety and efficacy of CBA-1205 in the following five parts in a stepwise manner:

Part 1

  • In Part 1, safety and tolerability in patients with Solid Tumor where no standard treatment is available, or who are intolerable or non-responder to the standard treatment will be evaluated. Initial dose for Part 2 will be determined.

Part 2

  • In Part 2, safety and tolerability in patients with advanced and/or recurrent Hepatocellular Carcinoma which are unresectable, or who are intolerable or non-responder to the standard treatment will be evaluated. Recommended dose in this population will be determined.

Part 3

  • In Part 3, safety and efficacy at the recommended dose in patients with advanced and/or recurrent Hepatocellular Carcinoma which are unresectable, or who are intolerable or non-responder to the standard treatment will be evaluated.

Part 4

  • In Part 4, safety and efficacy in patients with Malignant Melanoma who are refractory or intolerant to standard therapy.

Part 5

  • In Part 5, safety, tolerability and the recommended dose of the study drug in patients with Pediatric Cancer where no standard treatment is available, or who are intolerable or non-responder to the standard treatment will be evaluated.

PK analysis

03

Conditions studied

  • Solid Tumors
  • Hepatocellular Carcinoma (HCC)
  • Malignant Melanoma
  • Pediatric Cancer

Keywords

  • DLK1
  • First in human
  • Phase I
  • Antibody
  • solid tumor
  • Hepatocellular Carcinoma
  • CBA-1205
  • Melanoma
  • Pediatric Cancer
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:(Part 1-4)

  • Patients who provide voluntary written to participate in the study
  • Patients with an (ECOG) performance status (PS) of≤1
  • Patients with preserved renal function as evidenced by laboratory data obtained within 7 days before enrollment (creatinine: ≤ ×1.5)
  • Patients who meet the following laboratory criteria of bone marrow function as evidenced by laboratory data obtained within 7 days before enrollment: ;≥1500/μL, count; ≥75000/μL, ;≥9.0 g/dL.
  • Patients having Solid Tumors with no standard therapy available or or intolerable to standard therapy (Part2, 3)
  • Patients with A or B (Part2, 3)
  • Patients with Malignant Melanoma who are refractory or intolerant to standard therapy (Part 4)

Inclusion Criteria:(Part 5)

  • Patients who provide voluntary written informed consent to participate in the study from both the subject (if aged 16 years or older) and their legal representatives
  • Japanese patients aged 2 years or older and under 20 years at the time of informed consent
  • Patients with a Lansky Performance Status (LPS) of ≥70 (for patients aged 15 years or younger) or a Performance Status (KPS) of ≥70 (for patients aged 16 years or older)
  • Patients with preserved renal function as evidenced by laboratory data obtained within 7 days before enrollment ( ≥60 mL/min/1.73 m²)
  • Pediatric patients with cancers with no standard therapy available or refractory or intolerable to the standard therapy

Exclusion criteria: (Part1-5)

  • Patients who have undergone major surgery within 28 days before enrollment
  • Patients who have received anticancer treatment with surgical therapy, radiation therapy, and/or drug therapy within 14 days before enrollment
  • Patients who have received anticancer treatment with , etc. within 28 days before enrollment
  • Patients with Grade 2 or higher concurrent disease or prior therapy-related toxicity
  • Patients who have received any other product within 28 days before enrollment
  • Patients with current or previous inadequately controlled or cardiac disease
  • Patients who, in the opinion of the investigator or subinvestigator, is not appropriate
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    CBA-1205: Part 1

    CBA-1205 injection is administered at 2-week intervals in seven cohorts (0.1, 0.3, 1, 3, 10, 20, 30 mg/kg) in patients with solid tumor. Note: In the study treatment period, CBA-1205 is intravenously administered at 2-week intervals in a 28-day cycle.

    Drug: CBA-1205 Part 1

  • Experimental
    CBA-1205: Part 2

    CBA-1205 (20, 30 mg/kg) injection is administered at 2-week intervals in 28-day cycles in patients with HCC . Note: The study drug is administered at 2-week intervals until any of the criteria for discontinuation of study treatment are met.

    Drug: CBA-1205 Part 2

  • Experimental
    CBA-1205: Part 3

    CBA-1205 injection is administered at 2-week intervals in 28-day cycles in patients with HCC. Note: The study drug is administered at 2-week intervals until any of the criteria for discontinuation of study treatment are met.

    Drug: CBA-1205 Part 3

  • Experimental
    CBA-1205 : Part 4

    CBA-1205 injection is administered at 2-week intervals in 28-day cycles in patients with Malignant Melanoma. Note: The study drug is administered at 2-week intervals until any of the criteria for discontinuation of study treatment are met.

    Drug: CBA-1205 Part 4

  • Experimental
    CBA-1205: Part 5

    CBA-1205 injection is administered at 2-week intervals in 28-day cycles in patients with Pediatric Cancer. Note: The study drug is administered at 2-week intervals until any of the criteria for discontinuation of study treatment are met.

    Drug: CBA-1205 Part 5

Interventions

  • DrugCBA-1205 Part 1

    CBA-1205: 0.1, 0.3, 1, 3, 10, 20, 30 mg/kg (Intravenous solution)

  • DrugCBA-1205 Part 2

    CBA-1205: 20 mg/kg and 30 mg/kg (Intravenous solution)

  • DrugCBA-1205 Part 3

    CBA-1205: 30 mg/kg (Intravenous solution)

  • DrugCBA-1205 Part 4

    CBA-1205: 20 mg/kg (Intravenous solution)

  • DrugCBA-1205 Part 5

    CBA-1205: 10 mg/kg (The initial cohort, Intravenous solution)

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity

    DLTs are assessed according to CTCAE v.5.0 during the first cycle (28 days).

    Time frame: Part 1, 2 and 5 - Dose limiting toxicity : For 28 days after the first dose of study treatment

  2. Adverse Event

    An adverse event is any untoward or unintended sign, symptom, or disease in a subject administered an investigational product, whether or not it is related to the investigational product

    Time frame: Adverse event : Maximum 12 months

Secondary outcomes

  1. Serum CBA-1205 concentration

    Blood samples are collected to assess the serum concentration of CBA-1205.

    Time frame: From Day 1 to Day 43 (or until Discontiuation of treatment)

  2. Immunogenicity

    Blood samples are collected to assess the serum anti-CBA-1205 antibody.

    Time frame: From Day1 to Day 43 (or until Discontiuation of treatment)

  3. Efficacy

    Antitumor response evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Tumor markers

    Time frame: Screening, Day 1 of Cycle 2 and 3, and Day 1 of even-numbered cycles from Cycle 4 onward until treatment discontinuation. Maximum 12 months

Other outcomes

  1. Exploration of biomarkers:

    Exploration of biomarkers: Delta-like 1 homolog (DLK1)-related marker

    Time frame: Baseline through disease progression assessed (Maximum 12 months.)

07

Study locations

5 of 5 sites recruiting
08

References and documents

Publications

  • Nakamura K, Takahashi K, Sakaguchi I, Satoh T, Zhang L, Yanai H, Tsukumo Y. A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models. Int J Mol Sci. 2024 Dec 19;25(24):13627. doi: 10.3390/ijms252413627. PubMed 39769389 ↗
  • Katsuya Y, Ikeda M, Koyama T, Sato J, Okada M, Matsubara N, Kondoh C, Mukohara T, Watanabe K, Kotani D, Ogawa Y, Taoka S, Yamamoto N. A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors. Cancer Sci. 2025 Apr;116(4):1012-1022. doi: 10.1111/cas.16454. Epub 2025 Jan 20. PubMed 39832211 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jun 2027, 84 months after the start.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 84 months is above that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 10, 2024
StartActual
Jun 1, 2020
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06636435
Lead sponsor
Chiome Bioscience Inc.
Responsible party
Sponsor
First posted
Oct 10, 2024
Start date
Jun 1, 2020
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

Tanaka Miseri Chiome Bioscience Inc.
Contact
ir@chiome.co.jp
+81-3-6383-3561
General Affairs and Human Resources Department Chiome Bioscience Inc.
Contact
+81-3-6383-3561

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion